BACKGROUND: The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood. METHODS: We obtained DNA samples from leukemia cells in 91 patients with chronic lymphocytic leukemia and performed massively parallel sequencing of 88 whole exomes and whole genomes, together with sequencing of matched germline DNA, to characterize the spectrum of somatic mutations in this disease. RESULTS: Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients). SF3B1 mutations occurred primarily in tumors with deletions in chromosome 11q, which are associated with a poor prognosis in patients with chronic lymphocytic leukemia. We further discovered that tumor samples with mutations in SF3B1 had alterations in pre-messenger RNA (mRNA) splicing. CONCLUSIONS: Our study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocytic leukemia.
BACKGROUND: The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood. METHODS: We obtained DNA samples from leukemia cells in 91 patients with chronic lymphocytic leukemia and performed massively parallel sequencing of 88 whole exomes and whole genomes, together with sequencing of matched germline DNA, to characterize the spectrum of somatic mutations in this disease. RESULTS: Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients). SF3B1 mutations occurred primarily in tumors with deletions in chromosome 11q, which are associated with a poor prognosis in patients with chronic lymphocytic leukemia. We further discovered that tumor samples with mutations in SF3B1 had alterations in pre-messenger RNA (mRNA) splicing. CONCLUSIONS: Our study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocytic leukemia.
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Renee D Paulsen; Deena V Soni; Roy Wollman; Angela T Hahn; Muh-Ching Yee; Anna Guan; Jayne A Hesley; Steven C Miller; Evan F Cromwell; David E Solow-Cordero; Tobias Meyer; Karlene A Cimprich Journal: Mol Cell Date: 2009-07-31 Impact factor: 17.970
Authors: Timothy J Ley; Elaine R Mardis; Li Ding; Bob Fulton; Michael D McLellan; Ken Chen; David Dooling; Brian H Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E Larson; Dan C Koboldt; Craig Pohl; Scott Smith; Amy Hawkins; Scott Abbott; Devin Locke; Ladeana W Hillier; Tracie Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua Conyers; Nathan Sander; Xiaoqi Shi; John R Osborne; Patrick Minx; David Gordon; Asif Chinwalla; Yu Zhao; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark Watson; Jack Baty; Jennifer Ivanovich; Sharon Heath; William D Shannon; Rakesh Nagarajan; Matthew J Walter; Daniel C Link; Timothy A Graubert; John F DiPersio; Richard K Wilson Journal: Nature Date: 2008-11-06 Impact factor: 49.962
Authors: Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer Journal: Blood Date: 2012-03-06 Impact factor: 22.113
Authors: Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman Journal: Clin Cancer Res Date: 2012-05-23 Impact factor: 12.531
Authors: Sarah Abu Kar; Anna Jankowska; Hideki Makishima; Valeria Visconte; Andres Jerez; Yuka Sugimoto; Hideki Muramatsu; Fabiola Traina; Manuel Afable; Kathryn Guinta; Ramon V Tiu; Bartlomiej Przychodzen; Hirotoshi Sakaguchi; Seiji Kojima; Mikkael A Sekeres; Alan F List; Michael A McDevitt; Jaroslaw P Maciejewski Journal: Haematologica Date: 2012-07-06 Impact factor: 9.941
Authors: Lili Wang; Alex K Shalek; Mike Lawrence; Ruihua Ding; Jellert T Gaublomme; Nathalie Pochet; Petar Stojanov; Carrie Sougnez; Sachet A Shukla; Kristen E Stevenson; Wandi Zhang; Jessica Wong; Quinlan L Sievers; Bryan T MacDonald; Alexander R Vartanov; Natalie R Goldstein; Donna Neuberg; Xi He; Eric Lander; Nir Hacohen; Aviv Regev; Gad Getz; Jennifer R Brown; Hongkun Park; Catherine J Wu Journal: Blood Date: 2014-04-28 Impact factor: 22.113
Authors: Jane Houldsworth; Asha Guttapalli; Venkata Thodima; Xiao Jie Yan; Geetu Mendiratta; Tania Zielonka; Gouri Nanjangud; Weiyi Chen; Sujata Patil; Anthony Mato; Jennifer R Brown; Kanti Rai; Nicholas Chiorazzi; R S K Chaganti Journal: Leuk Lymphoma Date: 2013-11-12